Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
AIDS ; 17(5): 645-52, 2003 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-12646786

RESUMEN

OBJECTIVE: To evaluate the potential use of 2-long terminal repeats (LTR) HIV circular DNA quantification for the monitoring of ongoing virus replication in treated HIV-1-infected patients. DESIGN AND METHODS: In a longitudinal setting, where the natural course of HIV-1 infection was in most cases disrupted by continuous or discontinuous antiviral therapy, 2-LTR circles of HIV-1 DNA were quantified in serial peripheral blood mononuclear cell samples, selected in retrospect from 16 patients with chronic HIV-1 infection, using quantitative real-time PCR. We compared variations of 2-LTR circle level with concomitant variations in plasma viral RNA level and with the frequency of productively infected cells and chromosome associated proviral DNA copy numbers in patient's peripheral blood mononuclear cells. RESULTS: Antiviral treatment led to a sharp decrease in plasma viraemia and infectious cell frequency. In contrast, we found that levels of proviral DNA and 2-LTR circles were significantly lower under treatment only when groups of specimens that were homogeneous, with respect both to plasma viraemia and infectious cell frequency, were compared. Moreover, during the time of undetectable plasma viraemia, scarcely any decline in proviral DNA or 2-LTR circle levels was observed. CONCLUSIONS: The low impact of antiviral treatment on 2-LTR circle levels in vivo, when plasma viraemia and infectious cell frequency both dramatically decline lead us to conclude that 2-LTR circles should not be used for the monitoring of recent viral replication in treated patients.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Monitoreo de Drogas/métodos , Infecciones por VIH/tratamiento farmacológico , Duplicado del Terminal Largo de VIH/efectos de los fármacos , VIH-1/fisiología , Recuento de Linfocito CD4 , Enfermedad Crónica , ADN Viral/sangre , Femenino , Infecciones por VIH/virología , Humanos , Leucocitos Mononucleares/virología , Estudios Longitudinales , Masculino , Provirus/aislamiento & purificación , Viremia/tratamiento farmacológico , Replicación Viral/efectos de los fármacos
2.
J Gen Virol ; 86(Pt 9): 2495-2506, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16099908

RESUMEN

Live-attenuated viruses have typically been generated from pathogenic viruses by genetic modifications that modified their replicative capacity. The present study investigated whether modification of the antigenic properties of live-attenuated viruses might improve upon the protection that such vaccines afford against lentivirus infection. In a previous study, random amino acid substitutions were introduced into the transmembrane envelope glycoprotein of the feline immunodeficiency virus (FIV), within a highly conserved domain (principal immunodominant domain) bearing immunodominant B-cell epitopes. Amongst a wide set of mutants, mutations that modified antibody specificity without abolishing infectivity ex vivo were selected. In the present study, two such mutants, TN14 and TN92, were evaluated for their replicative capacities and pathogenic properties in vivo in comparison with the parental virus, FIV 34TF10. No significant differences in viral load were observed between mutant and parental viruses. After 1 year of infection, all animals were subjected to a heterologous intraclade superinfection with a primary strain of FIV. Whilst both parental and modified viruses protected cats from high viral loads after superinfection, the TN92 virus afforded a higher degree of protection (P=0.0079). Such improvement in protection might correlate with a decrease in the immunogenicity of a B-cell epitope potentially involved in antibody enhancement of infection.


Asunto(s)
Enfermedades de los Gatos/prevención & control , Productos del Gen env/genética , Virus de la Inmunodeficiencia Felina/inmunología , Infecciones por Lentivirus/veterinaria , Vacunas Atenuadas/inmunología , Vacunas Virales/inmunología , Secuencia de Aminoácidos , Sustitución de Aminoácidos , Animales , Anticuerpos Antivirales/sangre , Secuencia de Bases , Enfermedades de los Gatos/inmunología , Enfermedades de los Gatos/virología , Gatos , Epítopos de Linfocito B/inmunología , Productos del Gen env/administración & dosificación , Productos del Gen env/inmunología , Virus de la Inmunodeficiencia Felina/genética , Virus de la Inmunodeficiencia Felina/patogenicidad , Epítopos Inmunodominantes/inmunología , Infecciones por Lentivirus/inmunología , Infecciones por Lentivirus/prevención & control , Infecciones por Lentivirus/virología , Datos de Secuencia Molecular , Vacunación , Vacunas Atenuadas/administración & dosificación , Vacunas de ADN/administración & dosificación , Vacunas de ADN/inmunología , Vacunas Virales/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA